All In Biotech

Drug Trial Radar · NCT05446870

Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

160

Actual

Start

Jul 25, 2022

Primary completion

Dec 20, 2023

Study completion Oct 16, 2024

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate in participants with high-grade serous ovarian cancer (HGSOC), whether the reduction from baseline in circulating tumor deoxyribonucleic acid (ctDNA) at Cycle 3 (ΔctDNA) is larger in participants receiving MK-4830 + pembrolizumab in combination with standard of care (SOC) therapy than in those receiving pembrolizumab + SOC therapy.

Conditions

  • High-grade Serous Ovarian Carcinoma
  • Ovarian Carcinoma

Interventions

  • PembrolizumabBiological

    200 mg by IV infusion on Day 1 of each 21-day cycle

  • PaclitaxelDrug

    175 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle

  • CarboplatinDrug

    AUC 5 to 6 by IV infusion on Day 1 of each 21-day cycle

  • AvastinBiological

    According to local practice and at the choice of the investigator.

  • MK-4830Biological

    800 mg by IV infusion on Day 1 of each 21-day cycle

  • DocetaxelDrug

    75 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (ctDNA)Time frame: Baseline and Week 7

Locations

45 sites in 11 countries. Site status is shown where the registry gives one.

  • University of Colorado Anschutz Medical Campus-Cancer Clinical Trials Office ( Site 0108)

    Aurora, Colorado

  • Mayo Clinic in Florida ( Site 0101)

    Jacksonville, Florida

  • Miami Cancer Institute at Baptist Health, Inc. ( Site 0110)

    Miami, Florida

  • Northwestern Memorial Hospital ( Site 0104)

    Chicago, Illinois

  • Washington University ( Site 0113)

    St Louis, Missouri

  • Rutgers Cancer Institute of New Jersey ( Site 0114)

    New Brunswick, New Jersey

  • Roswell Park Cancer Institute ( Site 0106)

    Buffalo, New York

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0116)

    Mineola, New York

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0107)

    New York, New York

  • Memorial Sloan Kettering Cancer Center ( Site 0102)

    New York, New York

  • Sanford Cancer Center-Gynecologic Oncology ( Site 0115)

    Sioux Falls, South Dakota

  • Fred Hutchinson Cancer Center ( Site 0100)

    Seattle, Washington

  • Antwerp University Hospital-Oncology ( Site 1301)

    Edegem, Antwerpen, Belgium

  • AZ Maria Middelares-IKG ( Site 1302)

    Ghent, Oost-Vlaanderen, Belgium

  • UZ Leuven ( Site 1300)

    Leuven, Vlaams-Brabant, Belgium

  • Centre Hospitalier de l'Université de Montréal ( Site 0300)

    Montreal, Quebec, Canada

  • McGill University Health Centre ( Site 0301)

    Montreal, Quebec, Canada

  • James Lind Centro de Investigación del Cáncer ( Site 0903)

    Temuco, Araucania, Chile

  • FALP ( Site 0905)

    Santiago, Region M. de Santiago, Chile

  • Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 0900)

    Santiago, Region M. de Santiago, Chile

  • ONCOCENTRO APYS-ACEREY ( Site 0904)

    Viña del Mar, Valparaiso, Chile

  • Rambam Health Care Campus-Gyneco-oncology unit ( Site 0602)

    Haifa, Israel

  • Shaare Zedek Medical Center ( Site 0601)

    Jerusalem, Israel

  • Sheba Medical Center-ONCOLOGY ( Site 0600)

    Ramat Gan, Israel

  • Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 0501)

    Milan, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Sperimentale Uro-Genitale ( Site 0

    Naples, Campania, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli-Ginecologia Oncologica ( Site 0502)

    Rome, Lazio, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 050

    Milan, Lombardy, Italy

  • Uniwersytecki Szpital Kliniczny w Poznaniu-Oddzial Ginekologii Onkologicznej ( Site 0709)

    Poznan, Greater Poland Voivodeship, Poland

  • Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 0701)

    Siedlce, Masovian Voivodeship, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Sit

    Warsaw, Masovian Voivodeship, Poland

  • Uniwersyteckie Centrum Kliniczne-Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Gi

    Gdansk, Pomeranian Voivodeship, Poland

  • Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 0708)

    Kielce, Świętokrzyskie Voivodeship, Poland

  • National Cancer Centre Singapore ( Site 1501)

    Singapore, Central Singapore, Singapore

  • National University Hospital ( Site 1502)

    Singapore, South West, Singapore

  • Seoul National University Hospital ( Site 0801)

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 0800)

    Seoul, South Korea

  • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1101)

    Barcelona, Spain

  • Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1103)

    Hospitalet, Barcelona, Spain

  • Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1104)

    Madrid, Madrid, Comunidad de, Spain

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.